Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Abemaciclib is an ATP-competitive, reversible kinase inhibitor selective for CDK4 and CDK6 that has shown antitumor activity as a single agent in hormone receptor positive (HR+) metastatic breast cancer in clinical trials. Here, we examined the mechanistic effects of abemaciclib treatment using in v...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres-Guzmán, Raquel, Calsina, Bruna, Hermoso, Ana, Baquero, Carmen, Alvarez, Beatriz, Amat, Joaquín, McNulty, Ann M., Gong, Xueqian, Boehnke, Karsten, Du, Jian, de Dios, Alfonso, Beckmann, Richard P., Buchanan, Sean, Lallena, María José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642494/
https://www.ncbi.nlm.nih.gov/pubmed/29050219
http://dx.doi.org/10.18632/oncotarget.17778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642494/
https://www.ncbi.nlm.nih.gov/pubmed/29050219
http://dx.doi.org/10.18632/oncotarget.17778

Ejemplares similares